Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul;73(1):8-15.
doi: 10.1007/s12020-021-02651-y. Epub 2021 Feb 15.

Phytochemicals in thyroid cancer: analysis of the preclinical studies

Stefania Bulotta  1 , Francesca Capriglione  1 , Marilena Celano  1 , Valeria Pecce  2 , Diego Russo  3 , Valentina Maggisano  1
Affiliations
Review

Phytochemicals in thyroid cancer: analysis of the preclinical studies

Stefania Bulotta et al. Endocrine. 2021 Jul.

Abstract

Purpose: In the search for novel effective compounds to use in thyroid cancer (TC) unresponsive to current treatment, attention has recently focused on plant-derived compounds with anticancer activity. In this review, we discuss the preclinical studies demonstrating phytochemical activity against thyroid cancer cells.

Results/conclusions: In particular, we describe their antiproliferative properties or ability to re-induce iodine retention, thus supporting their potential use as single agents or adjuvants in radioiodine-resistant thyroid cancer treatment.

Keywords: Combinatory treatment; Phytochemicals; Preclinical studies; Thyroid cancer.

PubMed Disclaimer

References

    1. S. Bulotta, M. Celano, G. Costante, D. Russo, Novel therapeutic options for radioiodine refractory thyroid cancer: re-differentiation and beyond. Curr. Opin. Oncol. 32, 13–19 (2020) - PubMed
    1. C. Durante, N. Haddy, E. Baudin, S. Leboulleux, D. Hartl, J.P. Travagli, B. Caillou, M. Ricard, J.D. Lumbroso, F. De Vathaire, M. Schlumberger, Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 91, 2892–2899 (2006) - PubMed
    1. S. Wächter, A. Wunderlich, B.H. Greene, S. Roth, M. Elxnat, S.A. Fellinger, F.A. Verburg, M. Luster, D.K. Bartsh, P. Di Fazio, Selumetinib activity in thyroid cancer cells: modulation of sodium iodide symporter and associated miRNAs. Int. J. Mol. Sci. 19(7), 2077 (2018) - PMC
    1. M.E. Cabanillas, M. Ryder, C. Jimenez, Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond. Endocr. Rev. 40(6), 1573–1604 (2019) - PubMed - PMC
    1. S. Bulotta, M. Celano, G. Costante, D. Russo, Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine. Endocrine 52, 214–221 (2016) - PubMed

LinkOut - more resources